Stocks
BridgeBio Financial Statements (BBIO) |
||||||||||
| BridgeBiosmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 04.05.2023 | 03.08.2023 | 02.11.2023 | 22.02.2024 | 02.05.2024 | 02.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 1.83 | 1.64 | 4.09 | 1.75 | 211.1 | 218.6 | |||
| Operating Income, bln rub | -126.2 | -146.1 | -157.7 | -177.4 | 3.74 | -477.5 | ||||
| EBITDA, bln rub | ? | -117.6 | -134.9 | -157.7 | -169.2 | 5.34 | -456.5 | |||
| Net profit, bln rub | ? | -176.8 | -157.9 | -177.0 | -168.1 | -35.2 | -538.3 | |||
| OCF, bln rub | ? | -144.3 | -113.4 | -145.2 | -124.8 | -219.5 | -602.9 | |||
| CAPEX, bln rub | ? | 0.012 | 0.428 | 0.431 | 0.435 | 1.49 | 2.79 | |||
| FCF, bln rub | ? | -144.3 | -113.8 | -145.7 | -125.3 | -221.0 | -605.7 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 124.6 | 144.2 | 161.2 | 177.8 | 205.5 | 688.7 | ||||
| Cost of production, bln rub | 0.651 | 0.599 | 0.598 | 0.598 | 1.89 | 3.69 | ||||
| R&D, bln rub | 93.5 | 108.1 | 125.1 | 130.2 | 141.0 | 504.4 | ||||
| Interest expenses, bln rub | 20.1 | 20.6 | 20.3 | 20.3 | 23.5 | 84.6 | ||||
| Assets, bln rub | 625.7 | 503.7 | 655.0 | 546.4 | 849.3 | 849.3 | ||||
| Net Assets, bln rub | ? | -1 226 | -1 362 | -1 208 | -1 354 | -1 050 | -1 050 | |||
| Debt, bln rub | 1 729 | 1 734 | 1 735 | 1 740 | 1 729 | 1 729 | ||||
| Cash, bln rub | 441.5 | 333.3 | 505.2 | 434.9 | 519.8 | 519.8 | ||||
| Net debt, bln rub | 1 287 | 1 400 | 1 230 | 1 305 | 1 209 | 1 209 | ||||
| Ordinary share price, rub | 16.6 | 17.2 | 26.4 | 40.4 | 30.9 | 26.9 | ||||
| Number of ordinary shares, mln | 152.6 | 160.5 | 163.3 | 174.5 | 178.7 | 178.7 | ||||
| Market cap, bln rub | 2 531 | 2 761 | 4 306 | 7 043 | 5 526 | 4 811 | ||||
| EV, bln rub | ? | 3 818 | 4 162 | 5 536 | 8 348 | 6 735 | 6 020 | |||
| Book value, bln rub | -1 254 | -1 390 | -1 234 | -1 381 | -1 075 | -1 075 | ||||
| EPS, rub | ? | -1.16 | -0.98 | -1.08 | -0.96 | -0.20 | -3.01 | |||
| FCF/share, rub | -0.95 | -0.71 | -0.89 | -0.72 | -1.24 | -3.39 | ||||
| BV/share, rub | -8.21 | -8.66 | -7.56 | -7.91 | -6.02 | -6.02 | ||||
| EBITDA margin, % | ? | -6 441% | -8 223% | -3 855% | -9 698% | 2.53% | -208.8% | |||
| Net margin, % | ? | -9 685% | -9 622% | -4 327% | -9 636% | -16.7% | -246.2% | |||
| FCF yield, % | ? | -16.1% | -17.7% | -11.6% | -7.51% | -11.0% | -12.6% | |||
| ROE, % | ? | 34.4% | 46.9% | 55.3% | 50.2% | 51.3% | 51.3% | |||
| ROA, % | ? | -67.4% | -126.9% | -101.9% | -124.4% | -63.4% | -63.4% | |||
| P/E | ? | -6.00 | -4.32 | -6.45 | -10.4 | -10.3 | -8.94 | |||
| P/FCF | -6.19 | -5.66 | -8.65 | -13.3 | -9.12 | -7.94 | ||||
| P/S | ? | 32.5 | 486.6 | 456.8 | 757.1 | 25.3 | 22.0 | |||
| P/BV | ? | -2.02 | -1.99 | -3.49 | -5.10 | -5.14 | -4.47 | |||
| EV/EBITDA | ? | -12.1 | -8.69 | -10.6 | -14.4 | -14.8 | -13.2 | |||
| Debt/EBITDA | -4.07 | -2.92 | -2.35 | -2.25 | -2.65 | -2.65 | ||||
| R&D/CAPEX, % | 779 267% | 25 254% | 29 034% | 29 937% | 9 449% | 18 106% | ||||
| CAPEX/Revenue, % | 0.66% | 26.1% | 10.5% | 24.9% | 0.71% | 1.27% | ||||
| BridgeBio shareholders | ||||||||||
